NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC

January 10, 2018

http://www.state.nj.us/humanservices/dmahs/boards/durb/

AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for October 18, 2017 meeting

IV. Secretary’s report

V. Old Business
   A. United Healthcare’s response to directed intervention denials breakdown
   B. Proposed protocol for safe and efficient use of opioid induced, chronic idiopathic, IBS-related constipation products

VI. New Business
   A. Proposed survey for Morphine Milligram Equivalent (MME) opioid dosing
   B. Proposed protocol for naltrexone extended release injection (Vivitrol®)
   C. Proposed survey for monitoring gabapentin/opioid utilization

VII. Informational Highlights/Reports
    2. Summary of DURB Action Items
    3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
       (b) Physician-administered drugs by amount paid/category
    4. Medication information:
       (a) Statin Use Raises Diabetes Risk ‘Even in High-Risk Patients’
       (b) New Study Shows Antidepressants Increase the Risk of Developing Type 2 Diabetes in Children and Youth
       (c) Pharmacies, PBMs, insurers call for opioid prescription policy changes
       (d) Opioids Not Only Answer for Pain Relief in the ER
       (e) Department of Justice Announces Significant Toll in Prosecuting Opioid Traffickers in Emergency Scheduling of All Fentanyls
       (f) New ACC/AHA High Blood Pressure Guidelines Lower Definition of Hypertension